Protalix presents Phase 1 data for gout drug PRX-115 at ACR meeting
Protalix BioTherapeutics (PLX) presented Phase 1 data for PRX-115, a gout drug, at the ACR meeting. The study showed dose-dependent exposure and sustained plasma uric acid levels below 6.0 mg/dL. The 36 mg dose maintained levels below target for up to 12 weeks. PRX-115 was generally well-tolerated. Phase 2 study RELEASE is ongoing, with top-line results expected in late 2027.
How this was made
The 30-second read
Why it matters
The data provides the first quantitative evidence of dose‑response and durability, which may influence analyst forecasts and investor sentiment.
Market read
First‑time Phase 1 results are a material catalyst for PLX, potentially affecting its valuation ahead of the Phase 2 readout.
What to watch
The upcoming Phase 2 design and competitive landscape of gout treatments could temper expectations.
Background
Protalix BioTherapeutics (NYSE American: PLX) is a biopharma focused on recombinant protein therapeutics, now reporting early data for its PEGylated uricase candidate.
Ticker impact
Protalix BioTherapeutics presented first‑time Phase 1 data for its gout drug PRX‑115 at the ACR meeting.
likely modest upside as investors price in potential Phase 2 success
Phase 1 data is new, material for a biotech and may lift sentiment ahead of the Phase 2 readout.
Market effects
Positive gout‑therapy data could boost interest in biotech firms developing uricase or enzyme therapies.
Limited to US‑listed biotech investors; no broader regional effect.
Modest, as gout prevalence is global but impact confined to niche biotech space.
Counterpoint
Phase 1 safety signals, such as an anaphylactic reaction, may raise concerns about tolerability.
Key entities
- companyProtalix BioTherapeutics Inc.
Developer of PRX‑115, a PEGylated uricase for uncontrolled gout.
